- Home
- BCAT vs IMTX Comparison
BCAT vs IMTX Comparison
Compare BCAT & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$9.80
Company Overview
Basic Information| Metric | BCAT | IMTX |
|---|---|---|
| Founded | 2020 | N/A |
| Country | United States | Germany |
| Employees | N/A | 407 |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | BCAT | IMTX |
|---|---|---|
| Price | $15.91 | $9.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 654.2K | 482.7K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 9.38% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.91 |
| P/E Ratio | $11.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.73 | $5.05 |
| 52 Week High | $16.05 | $12.41 |
Technical Indicators
Market Signals| Indicator | BCAT | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.54 | 45.89 |
| Support Level | $14.45 | $9.01 |
| Resistance Level | $15.89 | $10.64 |
| Average True Range (ATR) | 0.23 | 0.58 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 66.39 | 34.07 |
Price Performance
Historical Comparison BCAT
IMTX
About BCAT BlackRock Capital Allocation Term Trust of Beneficial Interest
BlackRock Capital Allocation Trust is a non-diversified, closed-end management investment company. The investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation.
About IMTX Immatics N.V.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.